The company’s shares were last trading at $0.20, up 11% intraday.
The initial results from the study has indicated that treatment with RECCE 327 was tolerated without animal deaths at both doses tested.
RECCE 327 is an antibiotic and anti-cancer drug that fights against viruses and bacteria, including superbugs, even after repeated use.
Recce is compiling pre-clinical efficacy and toxicology data across several anti-bacterial, anti-cancer and anti-viral models.
This is part of its planned Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) in the first half of CY2017.
The latest data is encouraging and supports the continuation of the current test protocols.
While there was no significant inhibition of growth in the cancer cells, the good toxicology data should give Recce the confidence to continue dosing RECCE 327 in mice.
The pre-clinical studies are on track to be completed by April 2017.